NTRK1 and hepatocellular carcinoma: Sorafenib blocks various receptor tyrosine kinases (RTKs), such as VEGFR, PDGFR, c-kit, Flt-3, and RET, and suppresses the activation of the MAPK and PI3K/Akt signaling pathways, which play important roles in HCC pathogenesis173.